Equities Research Analysts’ updated eps estimates for Thursday, September 21st:

Adamas Pharmaceuticals (NASDAQ:ADMS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

On Assignment (NASDAQ:ASGN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “On Assignment, Inc., through its first operating division, Lab Support, is a leading nationwide provider of temporary scientific professionals to laboratories in the biotechnology, pharmaceutical, food and beverage, chemical, and environmental industries. The company’s strategy is to serve the needs of targeted industries for quality assignments of temporary professionals. “

Coloplast A/S (NASDAQ:CLPBY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “

Community Trust Bancorp (NASDAQ:CTBI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Community Trust Financial Services Corporation was incorporated under the laws for the purpose of becoming a bank holding company for Community Trust Bank. The Company is intended to facilitate the Bank’s ability to serve its customers’ requirements for financial services. The primary activity of the Company currently is, and is expected to remain for the foreseeable future, the ownership and operation of the Bank. “

Equity Lifestyle Properties (NYSE:ELS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $98.00 target price on the stock. According to Zacks, “Equity Lifestyle Properties, Inc. is a self-administered, self-managed, real estate investment trust. “

Ericsson (NASDAQ:ERIC) was upgraded by analysts at BNP Paribas from a neutral rating to an outperform rating.

Alphabet (NASDAQ:GOOGL) had its positive rating reaffirmed by analysts at Susquehanna Bancshares Inc. They currently have a $1,200.00 target price on the stock.

Lumentum Holdings (NASDAQ:LITE) had its buy rating reaffirmed by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $70.00 price target on the stock.

Medifast (NYSE:MED) had its neutral rating reiterated by analysts at Sidoti. Sidoti currently has a $55.00 target price on the stock, up from their previous target price of $49.00.

Nokia Corporation (NYSE:NOK) was downgraded by analysts at BNP Paribas from a neutral rating to an underperform rating.

Vertex Pharmaceuticals (NASDAQ:VRTX) was downgraded by analysts at Vetr to a sell rating.

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.